Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Rapid Bacterial Infection Test Differentiates Between MRSA and MSSA in 53 Minutes

By LabMedica International staff writers
Posted on 18 Jul 2023

Methicillin-resistant Staphylococcus aureus (MRSA) is a critical pathogen responsible for numerous hospital-acquired infections, leading to complications and increased mortality rates. More...

The World Health Organization has estimated that patients infected with MRSA experience a mortality rate approximately 50% higher than those affected by non-resistant strains of Staphylococcus aureus. Therefore, swiftly and accurately determining whether the bacterial strain is methicillin-sensitive (MSSA) or resistant is crucial, particularly in emergency situations. Conducting MRSA/SA screening plays a significant role in mitigating health risks by curtailing contamination, breaking the chain of infection, and combating superbugs and antimicrobial resistance. Now, a rapid test provides differentiation between MRSA and MSSA in 53 minutes at the point of care.

The Vivalytic MRSA/MSSA Rapid Test from Randox Laboratories (Crumlin, UK) is a qualitative RT-PCR diagnostic test capable of identifying and distinguishing MRSA, MSSA, and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). Using a single cartridge, the Vivalytic MRSA/MSSA test facilitates a speedy diagnosis of MRSA infections, allowing for the immediate application of suitable antibiotic treatment and prevention of complications. In contrast to the 1-3 days required for traditional culture sampling, the Vivalytic test provides reliable results in less than an hour right at the point of care, making it highly applicable for use in emergency departments.

The Vivalytic analyzer has been designed to be user-friendly, delivering speedy analyses and ease of handling. The patient-to-result process comprises a simple four-step procedure. The test commences when the user scans or inputs sample information and then scans the cartridge code into the integrated Vivalytic software. The sample is then added into the cartridge slot, after which the lid is closed, and the cartridge is inserted into the Vivalytic. The touchscreen display provides a countdown to the completion of the test, and results are shown on the screen. Furthermore, multiple Vivalytic devices can be wirelessly linked, enabling simultaneous control of multiple tests, all reporting to a primary Vivalytic platform.

Related Links:
Randox Laboratories 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.